Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy

Leukemia volume 23, pages 486–491 (2009)Cite this article

Abstract

The recently described single-nucleotide polymorphism CT60, located in the 3′-untranslated region of the CTLA4 (cytotoxic T-lymphocyte antigen 4 ) gene, has been associated with susceptibility to several autoimmune diseases and has also been shown to be involved in immune responses following allogeneic stem cell transplantation (SCT). However, the contribution of the CTLA4 genotype to the control of minimal residual disease in patients with acute myeloid leukemia (AML) has yet to be explored. We investigated the association between the CTLA4 CT60 A/G genotype and the incidence of leukemic relapse in 143 adult patients with AML in first complete remission after the same chemotherapy protocol (CETLAM LAM’03). The CT60 AA genotype was associated with a higher rate of leukemic relapse (56.4 vs 35.6%, P=0.004; hazard ratio (HR)=2.64, 95% confidence interval (CI)=1.36–5.14) and lower overall survival at 3 years (39.4 vs 68.4%, P=0.004; HR=2.80, 95% CI=1.39–5.64). This is the first study to report an association between polymorphisms at CTLA-4 and AML relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Greenwald RJ, Freeman GJ, Sharpe AH . The B7 family revisited. Ann Rev Immunol 2005; 23: 515–548.

    Article  Google Scholar 

  2. Chen L . Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336–347.

    Article  CAS  PubMed  Google Scholar 

  3. Teft WA, Kirchhof MG, Madrenas J . A molecular perspective of CTLA-4 function. Ann Rev Immunol 2006; 24: 64–97.

    Article  Google Scholar 

  4. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 2003; 423: 506–511.

    Article  CAS  PubMed  Google Scholar 

  5. Torres B, Aguilar F, Franco E, Sánchez E, Sánchez-Román J, Jiménez-Alonso J et al. Association of the CT60 marker of the CTLA-4 gene with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 2211–2215.

    Article  CAS  PubMed  Google Scholar 

  6. Pérez-García A, De la Cámara R, Román-Gómez J, Jiménez-Velasco A, Encuentra M, Nieto JB et al. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 2007; 110: 461–467.

    Article  PubMed  Google Scholar 

  7. Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 2006; 165: 114–120.

    Article  CAS  PubMed  Google Scholar 

  8. Heward J, Gordon C, Allahabadia A, Barnett AH, Franklyn JA, Gough SC . The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus. Ann Rheum Dis 1999; 58: 193–195.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hudson LL, Rocca K, Song YW, Pandey JP . CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 2002; 111: 452–455.

    Article  CAS  PubMed  Google Scholar 

  10. Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nunez-Roldan A . CTLA-4 polymorphism in Spanish patients with rheumatoid arthritis. Tissue Antigens 1999; 53: 296–300.

    Article  CAS  PubMed  Google Scholar 

  11. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ . CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Grave's disease. J Immunol 2000; 165: 6606–6611.

    Article  CAS  PubMed  Google Scholar 

  12. Parks CG, Hudson LL, Cooper GS, Dooley MA, Treadwell EL, St Clair EW et al. CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States. Lupus 2004; 13: 784–791.

    Article  CAS  PubMed  Google Scholar 

  13. Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 2007; 68: 698–704.

    Article  CAS  PubMed  Google Scholar 

  14. Whiteway A, Corbett T, Anderson R, Macdonald I, Prentice HG . Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol 2003; 120: 442–451.

    Article  CAS  PubMed  Google Scholar 

  15. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Huurman VA, Unger WW, Koeleman BP, Oaks MK, Chandraker AK, Terpstra OT et al. Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin Exp Immunol 2007; 150: 487–493.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. O’Day SJ, Hamid O, Urba WJ . Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614–2627.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study has been financed by Grant FIS PI050939 from the Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo.

Author information

Authors and Affiliations

  1. Hematology Department, Institut Catalàd'Oncologia, Girona, L'Hospitalet and Badalona, Spain

    A Pérez-García, J J Berlanga, R Guardia, J M Ribera & D Gallardo

  2. Hematology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

    S Brunet, J Nomdedeu, M Hoyos & J Sierra

  3. Hematology Department, Hospital Clínico, Valencia, Spain

    M Tormo

  4. Hematology Department, Hospital Morales Meseguer, Murcia, Spain

    I Heras

  5. Hematology Department, Hospital Joan XXIII, Tarragona, Spain

    A Llorente

  6. Hematology Department, Hospital Clínic, Barcelona, Spain

    J Esteve

  7. Hematology Department, Hospital Son Dureta, Palma de Mallorca, Spain

    J Besalduch

  8. Hematology Department, Hospital Vall d'Hebrón, Barcelona, Spain

    J Bueno

Authors
  1. A Pérez-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Brunet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J J Berlanga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Tormo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Nomdedeu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Guardia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J M Ribera
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Heras
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Llorente
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Hoyos
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Esteve
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Besalduch
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Bueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D Gallardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

‘Grupo cooperativo para el estudio y tratamiento de las leucemias agudas y mielodisplasias’ (CETLAM)

Corresponding author

Correspondence to D Gallardo.

Additional information

The list of participant centres and current group members appears in Appendix 1.

Appendix 1

Appendix 1

The centers and investigators contributing to the CETLAM study were as follows: Institut Català d'Oncologia (ICO) Hospital Josep Trueta, Girona (David Gallardo, Ramón Guardia, Cristalina Fernández); Hospital de la Santa Creu i Sant Pau, Barcelona (Salut Brunet, Josep F Nomdédeu, Montserrat Hoyos, Anna Aventín, Jorge Sierra); Hospital Clínic, Barcelona (Jordi Esteve, Mireia Camós, María Rozman, Neus Villamor, Dolors Costa); ICO Hospital Germans Trias i Pujol, Badalona (Josep M Ribera, Isabel Granada, Albert Oriol); ICO/Duran i Reynals, L’Hospitalet de Llobregat (Joan Berlanga, Rafael Duarte, Esther Alonso); Hospital Vall d’Hebrón, Barcelona (Javier Bueno, Eva Sánchez, Teresa Vallespí); Hospital del Mar, Barcelona (Carmen Pedro, Lourdes Florensa, Francesc Soler); Clínica Teknon, Barcelona (Pilar Vivancos); Hospital Juan Canalejo, A Coruña (Pio Torres); Hospital Clínico, Málaga (M. Paz Queipo De Llano); Hospital Clínico Universitario, Valencia (Mar Tormo); Hospital Son Dureta, Palma (Joan Besalduch, Marta Barnués); Hospital Son Llatzer, Palma (Joan Bargay); Hospital Joan XXIII, Tarragona (Andreu Llorente, Lourdes Escoda); Hospital Arnau de Vilanova, Lleida (Antoni García-Guiñón); Hospital Verge de la Cinta, Tortosa (Llorenç Font); Hospital Mutua Terrassa, Terrassa (Josep M Martí-Tutusaus, Cristina Estany). The laboratory work has been carried out at the Alloreactivity Unit, Laboratori de Recerca Translacional, ICO (Arianne Pérez-García, David Gallardo).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pérez-García, A., Brunet, S., Berlanga, J. et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 23, 486–491 (2009). https://doi.org/10.1038/leu.2008.339

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.339

Keywords

This article is cited by

Search

Advanced search

Quick links